# US 2015/0104532 A1 · Composition to Enhance HDL Cholesterol and to Decrease Intima-Media Thickening in animals and Humans and a Method for its Preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104532 A1
- Document ID: US20150104532A1
- Status: Published application
- Kind: A1
- Application number: 14/572,711
- Filed: 2014-12-16
- Published: 2015-04-16
- Earliest claimed: 2003-03-03
- Assignees: Arjuna Natural Extracts, Ltd.
- Applicants: Arjuna Natural Extracts, Ltd.
- Inventors: Benny ANTONY
- Web page: https://patentgrep.com/patent/US20150104532A1

## CPC

- A61K 36/47: Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/78: Saururaceae (Lizard's-tail family)
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of producing a product to correct hypercholesterolemia including pulping fruits of Emblica officinalis with demineralized water to create a slurry. The slurry is treated with pectinase. The pectinase-treated slurry is filtered to create a solution. The solution is concentrated to create a product. A product having an extract of Emblica officinalis for prophylactic and for therapeutic treatment of coronary diseases, atherosclerosis, hypothyroidism and hyperthyroidism.

## Claims

### Claim 1

A method of decreasing inflammation in a human comprising administering an extract of Emblica officinalis, the extract prepared by a method comprising:
pulping fruits of Emblica officinalis with demineralized water to create a slurry;
treating the slurry with pectinase;
filtering the slurry to create a solution; and
concentrating the solution to generate the extract of Emblica Officinalis.

### Claim 2

A method of decreasing CRP level in a human subject comprising administering an extract of Emblica officinalis, the extract prepared by a method comprising:
pulping fruits of Emblica officinalis with demineralized water to create a slurry;
treating the slurry with pectinase;
filtering the slurry to create a solution; and
concentrating the solution to generate the extract of Emblica officinalis.

### Claim 3 (depends on 2)

The method of decreasing CRP level of claim 2, wherein a decrease in CRP level ranges from about 4.2% to about 88% following administration of the extract of Emblica officinalis.

### Claim 4 (depends on 2)

The method of decreasing CRP level of claim 2, wherein a decrease in CRP level ranges from about 20% to about 60% following administration of the extract of Emblica officinalis.

### Claim 5 (depends on 2)

The method of decreasing CRP level of claim 2, wherein a decrease in CRP level ranges from about 25% to about 45% following administration of the extract of Emblica officinalis.

### Claim 6 (depends on 2)

The method of decreasing CRP level of claim 2, wherein a decrease in CRP level is about 4.2 % following administration of the extract of Emblica officinalis.

### Claim 7 (depends on 2)

The method of decreasing CRP level of claim 2, wherein a decrease in CRP level is about 88% following administration of the extract of Emblica officinalis.

### Claim 8 (depends on 2)

The method of decreasing CRP level of claim 2, wherein a CRP level ranges from about 1 mg CRP per liter to about 4.5 mg CRP per liter following administration of the extract of Emblica officinalis.

### Claim 9

A method of decreasing CRP level in a human subject having coronary artery disease comprising administering the extract of Emblica officinalis to the human subject, the extract prepared by a method comprising:
pulping fruits of Emblica officinalis with demineralized water to create a slurry;
treating the slurry with pectinase;
filtering the slurry to create a solution; and
concentrating the solution to generate the extract of Emblica officinalis.

### Claim 10

A method of decreasing risk of myocardial infarction in a human subject comprising administering the extract of Emblica officinalis, the extract prepared by a method comprising:
pulping fruits of Emblica officinalis with demineralized water to create a slurry;
treating the slurry with pectinase;
filtering the slurry to create a solution; and
concentrating the solution to generate the extract of Emblica officinalis.

### Claim 11

A method of decreasing risk of stroke in a human subject comprising administering the extract of Emblica officinalis, the extract prepared by a method comprising:
pulping fruits of Emblica officinalis with demineralized water to create a slurry;
treating the slurry with pectinase;
filtering the slurry to create a solution; and
concentrating the solution to generate the extract of Emblica officinalis.
